Clinical trial NCT03766672: Characterization of the Genetic Profile of Type 2 Endometrial Carcinoma in Martinique
Official title: Characterization of the Genetic Profile of Type 2 Endometrial Carcinoma in Martinique
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Endometrial Neoplasms
Keywords: Endometrial carcinoma
Lead sponsor: University Hospital Center of Martinique
Sponsor class: OTHER
Collaborators: name: Martinique Cancer Registry
First posted: 2018-12-06
Enrollment: 30
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women aged more 18 years living in Martinique with a type 2 endometrial cancer confrimed by with anatomopathological reports.

Brief summary: In Martinique, about 33 new cases are diagnosed per year, with a high incidence rate of type 2 endometrial carcinoma which has a poor prognosis with few therapeutic options. Although targeted therapies are used in many types of cancer, they are still possible a minority of patients. In current practice, endometrial cancers do not benefit these therapies. Characterization of the molecular mechanisms involved in the genesis of type 2 endometrial carcinoma could help to identify biomarkers predictive of a response to targeted therapies. We propose to identify the genetic profile of type 2 endometrial carcinomas in Martinique.

Detailed description: Type 2 endometrial carcinomas are often diagnosed at advanced stages, with an high risk of metastatic recurrence and death even when diagnosed at early stages. They also have few therapeutic options. The Characterize the mutations responsible of cancer development has led to develope "precision medicine" that targets "actionable genes" by a drug. This concept of actionable mutation refers to a change in the DNA molecule that can predict the response to a drug defined as targeted therapy. Although targeted therapies are used in many types of cancer, they still target a minority of patients. Some tumor sites still do not benefit from these treatments. Specifically, type 2 endometrial cancers that have poor prognosis with few therapeutic options. The characterization of molecular mechanisms, by Next Generation Sequencing (NGS), involved in the carcinogenesis of endometrial cancers, particularly type 2 cancers, should allow the identification of predictive biomarkers for response to certain targeted therapies.

Eligibility criteria: Inclusion Criteria:

* Major subject living in Martinique with the following characteristics :

  * Patients with type 2 endometrial cancer, with anatomopathological confirmation
  * Affiliate or beneficiary of french social security.
  * Free, informed with a written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any research required by the research).

Exclusion Criteria:

* Type 1 adenocarcinoma
* Patients not affiliated to french social security
* Refusal to participate.

Primary outcomes:
measure: Number of biomarkers identified by Next Generation Sequencing involved in type 2 endometrial tumors in Martinique
timeFrame: 24 Months
Secondary outcomes:
Other outcomes:
Locations:
city: Fort-de-France
country: Martinique
facility: Chu Martinique
Study officials:
affiliation: CHU Martinique
name: Medhi JEAN-LAURENT, MD
role: PRINCIPAL_INVESTIGATOR
References: